| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,500,000 |
| Market
Cap: |
1.95(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$35.77 - $65 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
32,136 |
465,065 |
655,744 |
1,062,982 |
| Total Sell Value |
$1,503,716 |
$26,033,932 |
$35,438,128 |
$50,015,597 |
| Total People Sold |
3 |
7 |
9 |
11 |
| Total Sell Transactions |
5 |
17 |
34 |
71 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Liawatidewi Yakob |
EVP Corp Admin Center |
• – – |
2022-03-16 |
4 |
D |
$34.22 |
$55,402 |
D/D |
(1,619) |
62,413 |
|
- |
|
| Luo Mary Z. |
CEO & Chief Scientific Officer |
• • • |
2022-03-16 |
4 |
D |
$34.22 |
$356,778 |
I/I |
(10,426) |
1,505,571 |
|
- |
|
| Luo Mary Z. |
CEO & Chief Scientific Officer |
• • • |
2022-03-16 |
4 |
D |
$34.22 |
$863,747 |
D/D |
(25,241) |
2,357,782 |
|
- |
|
| Zasloff Michael A |
Director |
– • – |
2022-03-16 |
4 |
S |
$33.71 |
$337,069 |
D/D |
(10,000) |
47,206 |
|
-8% |
|
| Zasloff Michael A |
Director |
– • – |
2022-03-16 |
4 |
OE |
$17.11 |
$171,100 |
D/D |
10,000 |
57,206 |
|
- |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-03-15 |
4 |
D |
$34.74 |
$208,058 |
D/D |
(5,989) |
114,144 |
|
- |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,991 |
120,133 |
|
- |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-03-15 |
4 |
AS |
$34.46 |
$272,248 |
D/D |
(7,900) |
98,142 |
|
6% |
|
| Liawatidewi Yakob |
EVP Corp Admin Center |
• – – |
2022-03-15 |
4 |
D |
$34.74 |
$54,160 |
D/D |
(1,559) |
64,032 |
|
- |
|
| Liawatidewi Yakob |
EVP Corp Admin Center |
• – – |
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
11,514 |
65,591 |
|
- |
|
| Prins Richard K |
Director |
– • – |
2022-03-15 |
4 |
S |
$34.02 |
$340,208 |
D/D |
(10,000) |
45,179 |
|
-6% |
|
| Prins Richard K |
Director |
– • – |
2022-03-15 |
4 |
OE |
$17.11 |
$171,100 |
D/D |
10,000 |
55,179 |
|
- |
|
| Luo Mary Z. |
CEO & Chief Scientific Officer |
• • • |
2022-03-15 |
4 |
D |
$34.74 |
$166,266 |
I/I |
(4,786) |
1,515,997 |
|
- |
|
| Luo Mary Z. |
CEO & Chief Scientific Officer |
• • • |
2022-03-15 |
4 |
A |
$0.00 |
$0 |
I/I |
32,412 |
1,520,783 |
|
- |
|
| Luo Mary Z. |
CEO & Chief Scientific Officer |
• • • |
2022-03-15 |
4 |
D |
$34.74 |
$512,728 |
D/D |
(14,759) |
2,383,023 |
|
- |
|
| Luo Mary Z. |
CEO & Chief Scientific Officer |
• • • |
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
76,914 |
2,397,782 |
|
- |
|
| Zhou Rong |
EVP, Production Center |
• – – |
2022-03-15 |
4 |
D |
$34.74 |
$57,390 |
D/D |
(1,652) |
82,313 |
|
- |
|
| Zhou Rong |
EVP, Production Center |
• – – |
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,658 |
83,965 |
|
- |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-03-07 |
4 |
AS |
$29.35 |
$382,313 |
D/D |
(13,026) |
106,042 |
|
20% |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-03-07 |
4 |
OE |
$13.35 |
$173,897 |
D/D |
13,026 |
119,068 |
|
- |
|
| Petersen Floyd F. |
Director |
– • – |
2022-03-01 |
4 |
AS |
$27.27 |
$13,635 |
D/D |
(500) |
76,873 |
|
34% |
|
| Zhou Rong |
EVP, Production Center |
• – – |
2022-02-25 |
4 |
AS |
$28.77 |
$381,087 |
D/D |
(13,246) |
70,307 |
|
27% |
|
| Zhou Rong |
EVP, Production Center |
• – – |
2022-02-25 |
4 |
OE |
$10.93 |
$76,510 |
D/D |
7,000 |
83,553 |
|
- |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-02-25 |
4 |
AS |
$27.95 |
$654,850 |
D/D |
(23,000) |
106,042 |
|
27% |
|
| Peters William J |
CFO, EVP & Treasurer |
• – – |
2022-02-25 |
4 |
OE |
$14.95 |
$343,850 |
D/D |
23,000 |
129,042 |
|
- |
|
954 Records found
|
|
Page 8 of 39 |
|
|
0.28 (0.69%) 
